TranS1 defends US antitrust claims against Blue Cross
MLex Summary: TranS1 opposed a motion to dismiss US antitrust claims accusing Blue Cross Blue Shield of conspiring to keep it out of the market for spinal fusions. “The Third Circuit in...To view the full article, register now.
Already a subscriber? Click here to view full article